Eventually, it is known that B4GALNT1 is a relatively ideal target, but targeting GPC3 and ERBB2 might lead to severe “on-target, off-tumor toxicity” in some tissues (Figure 4H). The gene discussed is GPC3; the disease is neoplasm.